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countries and several Asian ethnic 
groups. Vietnamese patients had the 
highest incidence of EGFR mutations, 
whereas Indian patients had the lowest 
while about half of Filipino patients 
harbored EGFR mutations.1 In addi-
tion, general epidemiology parameters 
were comprehensively collected from 
all seven countries including detailed 
smoking status.1 We have previously 
published that Vietnamese-American 
females had the highest percentages 
(65.5%) of never smokers among the 
the six Asian-American subgroups 
analyzed, whereas Japanese-American 
female NSCLC patients had the lowest 
proportion (19.3%) of never smokers 
and about half of Filipino-American 
female NSCLC patients were never-
smokers.2 Besides activating EGFR 
mutations, others targetable driver 
mutations such as rearrangement 
in ALK, ROS1, and RET are also 
found primarily in never-smokers. 
Therefore, would Professor Yang and 
his colleagues be able to provide the 
breakdown by smoking status among 
patients within each individual coun-
try and further breakdown of smoking 
status by sex within each of the seven 
countries.
Sai-Hong Ignatius Ou, MD, PhD
Medicine-Hematology-Oncology
Chao Family Comprehensive 
Cancer Center
Irvine, CA 
acids: E709, G719, S768, T790, and 
L858.2 Exon 19 deletions are less fre-
quently found in compound mutations in 
untreated patients.3 The p.L747S muta-
tion is also rare with only seven cases 
being reported in the COSMIC database 
(http://cancer.sanger.ac.uk/cancerge-
nome/projects/cosmic). The compound 
p.L747S and p.A750_K754del mutation 
was only reported in one case in the litera-
ture, in a 73-year-old asian woman with 
unknown smoking status or therapy infor-
mation.2 Exon 19 deletions are known to 
be associated with sensitivity to tyrosine 
kinase inhibitor (TKI) and tumors harbor-
ing p.L747S mutation are TKI resistant.4 
We are reporting for the first time the 
Erlotinib response in a TKI-naive patient 
with a compound TKI-resistant and sen-
sitive mutation. The patient is currently 
in remission and still receiving Erlotinib 
therapy. It should be noted that cells car-
rying p.L747S mutation may become 
predominate after initial TKI response 
because of clonal selection of tumor cells 
carrying this p.L747S-resistant mutation.
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FIGURE 3. Computed Tomography 
images of the initial presentation (A) and 
2 months post-Erlotinib treatment (B) of 
the lung nodule.
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I congratulate Professor Yang 
and his colleagues in successfully 
performed a multinational large-scale 
molecular epidemiology in the fre-
quency of activating EGFR mutations 
in treatment-naïve advanced adeno-
carcinoma of the lung in seven Asian 
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PIONEER study, just more than half 
of all patients were never-smokers 
(52.6% [n = 779/1482]) and just more 
than one-fifth were regular smokers 
(22.1% [n = 327/1482]). Of the seven 
Asian countries/regions included in 
the PIONEER study, Taiwan had the 
greatest proportion of never-smokers 
(65.7%) and Vietnam had the low-
est proportion of never-smokers 
(31.4%). Similarly, Taiwanese females 
with NSCLC had the highest propor-
tion of never-smokers (97.8%) and 
Vietnamese males had the lowest pro-
portion of never-smokers (12.9%) of 
all the sex subgroups analyzed.1
Dr. Ou et al. observed driver muta-
tions in EGFR, anaplastic lymphoma 
kinase (ALK), gene encoding the proto-
oncogene tyrosine-protein kinase ROS 
enzyme (ROS1), and RET proto-ocogene 
(RET) primarily in never-smokers.2 In 
the PIONEER study, EGFR mutation 
status was evaluable in tumors from 1450 
of 1482 patients (97.8%). By country, 
EGFR mutation frequency was highest 
in patients from Vietnam (64.2% [n = 77 
of 120]) and lowest in patients from 
India (22.2% [n = 16 of 72]). Females 
had higher EGFR mutation frequency 
than males (61.1% [n = 384 of 628] and 
44.0% [n = 362 of 822], respectively) 
across all countries. Considering smok-
ing history, EGFR mutation frequency 
was highest among never-smokers 
(60.7% [n = 462 of 761]) compared with 
exsmokers (43.2% [n = 130 of 301]), 
occasional smokers (51.6% [n = 33 of 
64]), or regular smokers (37.3% [n = 121 
of 324]). EGFR mutation frequency was 
decreased as pack-year number increased 
(>0–10 pack-years: 57.9%; >50 pack-
years: 31.4%). A similar trend was 
observed by sex: males (0–10 pack-years: 
55.9% [n = 161 of 288], >10–30 pack-
years: 46.6% [n = 123 of 264], >30 pack-
years: 28.2% [n = 74 of 262]); females 
REFERENCES
 1. Shi Y, Au JS, Thongprasert S, et al. A prospective, 
molecular epidemiology study of EGFR muta-
tions in Asian patients with advanced non-small-
cell lung cancer of adenocarcinoma histology 
(PIONEER). J Thorac Oncol 2014;9:154–162.
 2. Ou SH, Ziogas A, Zell JA. A comparison study 
of clinicopathologic characteristics of Southern 
California Asian American Non-small Cell 
Lung Cancer (NSCLC) patients by smoking 
status. J Thorac Oncol 2010;5:158–168.
This study was funded by AstraZeneca.
Address for correspondence: Pan-Chyr Yang, MD, 
Department of Internal Medicine, National 
Taiwan University College of Medicine, National 
Taiwan University 1, Sec 1, Ren-Ai Road, Taipei 
10051, Taiwan. E-mail: pcyang@ntu.edu.tw
Copyright © 2014 by the International Association 
for the Study of Lung Cancer
ISSN: 1556-0864/14/0907-0e59
In Response:
Dr. Ou has requested smoking sta-
tus by country/region, and by sex within 
each country/region, for the patients 
with advanced non–small-cell lung can-
cer (NSCLC) who were included in a 
molecular ePIdemiOlogy study in Asian 
patients with advanced NSCLC of adEno 
histology to assess epidermal growth 
factor receptor (EGFR) mutation status 
(PIONEER) (NCT01185314), which 
analyzed data from 1482 eligible patients 
with advanced NSCLC.1 We are pleased 
to supply below the subgroup analyses 
of smoking status data by country/region 
and by sex within each country/region in 
reply to Dr. Ou’s request (Tables 1–3).
Dr. Ou et al. previously pub-
lished that Vietnamese-American 
females with NSCLC had the highest 
proportion of never-smokers (65.5%) 
among the six Asian-American 
subgroups analyzed in their study, 
whereas Japanese-American females 
with NSCLC had the lowest propor-
tion of never-smokers (19.3%).2 In the 
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(0–10 pack-years: 62.5% [n = 371 of 
594], >10–30 pack-years: 37.5% [n = 9 
of 24], >30 pack-years: 40.0% [n = 4 of 
10]). PIONEER researchers concluded 
that a patient’s ethnicity and smoking 
status/pack years were independent pre-
dictive factors for tumor EGFR mutation 
status. Other mutations were not explored 
in PIONEER.1
Given the limited sample sizes of 
these PIONEER subgroup analyses of 
smoking status data by country/region 
and by sex, we note that interpretation 
needs to be with caution, as the analyses 
may be subject to large sampling fluctu-
ations. We thank Dr. Ou for his congrat-
ulations and interest in our study and 
hope the above is informative and use-
ful for him and other interested parties.
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